Postoperative outcomes of gastric carcinoma with lymphoid stroma.
Gastric cancer
Gastric carcinoma with lymphoid stroma
Lymph node
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
21 May 2020
21 May 2020
Historique:
received:
28
03
2020
accepted:
13
05
2020
entrez:
23
5
2020
pubmed:
23
5
2020
medline:
9
3
2021
Statut:
epublish
Résumé
Gastric carcinoma with lymphoid stroma (GCLS) is a rare subtype of gastric cancer. There have been several reports demonstrating the favorable prognosis of early GCLS without lymph node metastasis (LNM) compared with gastric adenocarcinomas. However, it remains unknown whether advanced GCLS (AGCLS) with LNM has a similar prognosis and clinicopathological features. This study aimed to assess the clinicopathological features of GCLS of all stages. We retrospectively assessed 375 patients who were pathologically diagnosed with gastric cancer and underwent curative surgical resection at Tokyo Medical University, Japan, between September 2013 and October 2019. Of these patients, 357 (95.2%) patients were pathologically diagnosed with gastric adenocarcinomas, and 18 (4.8%) patients were diagnosed with GCLS. The GCLS patients (n = 18) were compared with the gastric adenocarcinoma patients (non-GCLS patients, control) (n = 357) in terms of their clinicopathological features and clinical outcome. The GCLS patients showed significantly predominant upper gastric locations (P = 0.003), lower number of LNM (P = 0.01), and better overall survival rate than the non-GCLS patients (P = 0.029). The predominant upper gastric locations (P = 0.0002), lower number of LNM (P = 0.003), and better overall survival rate (P = 0.04) were significantly correlated in the AGCLS with LNM patients compared with the advanced non-GCLS with LNM patients. For survival analyses, surgical procedure, tumor location, and numbers of positive LNM were adjusted by 1:1 propensity score matching. After adjustment, the overall survival rate was significantly higher in the AGCLS group than in the advanced non-GCLS group (P = 0.03). AGCLS has distinct clinicopathological features and clinical behavior that are similar to those of early GCLS. AGCLS with LNM patients showed a significantly lower number of LNM and a better survival rate than advanced non-GCLS with LNM patients. To our knowledge, this study is the first report to describe the clinicopathological features of AGCLS.
Sections du résumé
BACKGROUND
BACKGROUND
Gastric carcinoma with lymphoid stroma (GCLS) is a rare subtype of gastric cancer. There have been several reports demonstrating the favorable prognosis of early GCLS without lymph node metastasis (LNM) compared with gastric adenocarcinomas. However, it remains unknown whether advanced GCLS (AGCLS) with LNM has a similar prognosis and clinicopathological features. This study aimed to assess the clinicopathological features of GCLS of all stages.
METHODS
METHODS
We retrospectively assessed 375 patients who were pathologically diagnosed with gastric cancer and underwent curative surgical resection at Tokyo Medical University, Japan, between September 2013 and October 2019. Of these patients, 357 (95.2%) patients were pathologically diagnosed with gastric adenocarcinomas, and 18 (4.8%) patients were diagnosed with GCLS. The GCLS patients (n = 18) were compared with the gastric adenocarcinoma patients (non-GCLS patients, control) (n = 357) in terms of their clinicopathological features and clinical outcome.
RESULTS
RESULTS
The GCLS patients showed significantly predominant upper gastric locations (P = 0.003), lower number of LNM (P = 0.01), and better overall survival rate than the non-GCLS patients (P = 0.029). The predominant upper gastric locations (P = 0.0002), lower number of LNM (P = 0.003), and better overall survival rate (P = 0.04) were significantly correlated in the AGCLS with LNM patients compared with the advanced non-GCLS with LNM patients. For survival analyses, surgical procedure, tumor location, and numbers of positive LNM were adjusted by 1:1 propensity score matching. After adjustment, the overall survival rate was significantly higher in the AGCLS group than in the advanced non-GCLS group (P = 0.03).
CONCLUSION
CONCLUSIONS
AGCLS has distinct clinicopathological features and clinical behavior that are similar to those of early GCLS. AGCLS with LNM patients showed a significantly lower number of LNM and a better survival rate than advanced non-GCLS with LNM patients. To our knowledge, this study is the first report to describe the clinicopathological features of AGCLS.
Identifiants
pubmed: 32438924
doi: 10.1186/s12957-020-01878-9
pii: 10.1186/s12957-020-01878-9
pmc: PMC7243312
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102Références
Cancer. 1990 Sep 1;66(5):945-52
pubmed: 2386921
Gastric Cancer. 2017 Jan;20(1):1-19
pubmed: 27342689
Int J Cancer. 2006 Apr 1;118(7):1736-42
pubmed: 16217758
Cancer. 1994 May 1;73(9):2239-49
pubmed: 8168030
J Clin Pathol. 1994 Jun;47(6):538-40
pubmed: 8063937
Am J Pathol. 1992 Apr;140(4):769-74
pubmed: 1314023
Gastrointest Endosc. 2017 Apr;85(4):730-736
pubmed: 27475490
Mod Pathol. 2003 Jul;16(7):641-51
pubmed: 12861059
Gastric Cancer. 2015 Apr;18(2):246-55
pubmed: 24771002
World J Gastroenterol. 2014 Feb 7;20(5):1365-70
pubmed: 24574813
Appl Immunohistochem Mol Morphol. 2003 Jun;11(2):149-52
pubmed: 12777999
Jpn J Surg. 1983 May;13(3):177-83
pubmed: 6632390
Gastrointest Endosc. 2012 Oct;76(4):913-5
pubmed: 22196795
J Clin Oncol. 2004 Feb 15;22(4):664-70
pubmed: 14966089
J Gastroenterol Hepatol. 2009 Mar;24(3):354-65
pubmed: 19335785
J Surg Res. 2015 Apr;194(2):458-63
pubmed: 25592274
Gastroenterology. 2000 Jun;118(6):1031-8
pubmed: 10833477
Am J Pathol. 1991 Sep;139(3):469-74
pubmed: 1653517
Pathol Res Pract. 2011 Sep 15;207(9):529-37
pubmed: 21944426
Gastric Cancer. 2017 Sep;20(5):793-801
pubmed: 28205059
Dig Dis Sci. 2012 Nov;57(11):3032-4
pubmed: 22661271
Cancer. 1976 Jul;38(1):232-43
pubmed: 947518
Gan To Kagaku Ryoho. 2015 Nov;42(12):2021-3
pubmed: 26805251
Hum Pathol. 1990 Mar;21(3):325-32
pubmed: 2312109
J Gastric Cancer. 2018 Dec;18(4):400-408
pubmed: 30607303
Clin Gastroenterol Hepatol. 2015 Oct;13(10):1738-1744.e2
pubmed: 25912839
Gastroenterology. 2009 Sep;137(3):824-33
pubmed: 19445939
Mol Pathol. 2000 Oct;53(5):255-61
pubmed: 11091849
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
Gastroenterology. 2010 Jul;139(1):84-92.e2
pubmed: 20398662
Surg Endosc. 2017 Oct;31(10):4156-4164
pubmed: 28409376